Literature DB >> 29600041

Ablative therapy in oligometastatic non-small cell lung cancer-an editorial on recent evidence.

Mark Niglas1,2, Patrick Cheung1,2.   

Abstract

Entities:  

Year:  2018        PMID: 29600041      PMCID: PMC5863189          DOI: 10.21037/jtd.2017.12.119

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  Stereotactic radiotherapy in oligometastatic cancer.

Authors:  Thomas A C Kennedy; Mark T Corkum; Alexander V Louie
Journal:  Chin Clin Oncol       Date:  2017-09

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Authors:  Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

Review 7.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Authors:  Allison B Ashworth; Suresh Senan; David A Palma; Marc Riquet; Yong Chan Ahn; Umberto Ricardi; Maria T Congedo; Daniel R Gomez; Gavin M Wright; Giulio Melloni; Michael T Milano; Claudio V Sole; Tommaso M De Pas; Dennis L Carter; Andrew J Warner; George B Rodrigues
Journal:  Clin Lung Cancer       Date:  2014-05-15       Impact factor: 4.785

8.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

9.  The evolutionary history of lethal metastatic prostate cancer.

Authors:  Christopher Foster; Douglas Easton; Ultan McDermott; David C Wedge; G Steven Bova; Gunes Gundem; Peter Van Loo; Barbara Kremeyer; Ludmil B Alexandrov; Jose M C Tubio; Elli Papaemmanuil; Daniel S Brewer; Heini M L Kallio; Gunilla Högnäs; Matti Annala; Kati Kivinummi; Victoria Goody; Calli Latimer; Sarah O'Meara; Kevin J Dawson; William Isaacs; Michael R Emmert-Buck; Matti Nykter; Zsofia Kote-Jarai; Hayley C Whitaker; David E Neal; Colin S Cooper; Rosalind A Eeles; Tapio Visakorpi; Peter J Campbell
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

10.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

View more
  1 in total

1.  Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.

Authors:  Kaiyan Chen; Fanrong Zhang; Yun Fan; Guoping Cheng
Journal:  Onco Targets Ther       Date:  2020-09-04       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.